Ventilatory, hemodynamic and sedative effects of the α2 adrenergic agonist, dexmedetomidine

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Dexmedetomedine is a potent α2 adrenergic agonist which can reduce anesthetic requirements by over 90% in rats and dogs. This study examined the effects of various doses of dexmedetomidine on the following monitored variables in New Zealand white rabbits: arterial blood gases, mean arterial pressure, respiratory rate, heart rate, and level of sedation. Following the percutaneous insertion of arterial and venous catheters, 21 rabbits received an infusion of saline or dexmedetomidine (20, 80 or 320 μg/kg). Monitored variables were recorded at 5, 15, 30 and 60 min following the infusion. Dexmedetomidine produced significant dose-dependent increases in PaCO2 and level of sedation. There were significant decreases in heart rate, PaO2 and respiratory rate. There was no significant change in mean arterial pressure even at the highest (320 μg/kg) dose. To examine the ability of an α2 adrenergic antagonist to reverse the effects of dexmedetomidine, 5 rabbits initially received 320 μg/kg of dexmedetomidine as described above. Seven minutes after completion of the infusion, 900 μg/kg of the α2 adrenergic antagonist, idazoxan, was administered. This resulted in a prompt and sustained reversal of the hypercarbia and sedation produced by the dexmedetomidine.

Original languageEnglish (US)
Pages (from-to)1065-1071
Number of pages7
JournalNeuropharmacology
Volume30
Issue number10
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Dexmedetomidine
Adrenergic Agonists
Hypnotics and Sedatives
Hemodynamics
Adrenergic Antagonists
Respiratory Rate
Rabbits
Arterial Pressure
Heart Rate
Idazoxan
Hypercapnia
Anesthetics
Catheters
Gases
Dogs

Keywords

  • alpha adrenergic
  • anesthetics
  • intravenous
  • receptors
  • sympathetic nervous system
  • ventilation
  • α adrenoceptor agonist: dexmedetomidine

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Drug Discovery
  • Pharmacology

Cite this

Ventilatory, hemodynamic and sedative effects of the α2 adrenergic agonist, dexmedetomidine. / Zornow, Mark.

In: Neuropharmacology, Vol. 30, No. 10, 1991, p. 1065-1071.

Research output: Contribution to journalArticle

@article{79837528883e4619920ce57f60814e8f,
title = "Ventilatory, hemodynamic and sedative effects of the α2 adrenergic agonist, dexmedetomidine",
abstract = "Dexmedetomedine is a potent α2 adrenergic agonist which can reduce anesthetic requirements by over 90{\%} in rats and dogs. This study examined the effects of various doses of dexmedetomidine on the following monitored variables in New Zealand white rabbits: arterial blood gases, mean arterial pressure, respiratory rate, heart rate, and level of sedation. Following the percutaneous insertion of arterial and venous catheters, 21 rabbits received an infusion of saline or dexmedetomidine (20, 80 or 320 μg/kg). Monitored variables were recorded at 5, 15, 30 and 60 min following the infusion. Dexmedetomidine produced significant dose-dependent increases in PaCO2 and level of sedation. There were significant decreases in heart rate, PaO2 and respiratory rate. There was no significant change in mean arterial pressure even at the highest (320 μg/kg) dose. To examine the ability of an α2 adrenergic antagonist to reverse the effects of dexmedetomidine, 5 rabbits initially received 320 μg/kg of dexmedetomidine as described above. Seven minutes after completion of the infusion, 900 μg/kg of the α2 adrenergic antagonist, idazoxan, was administered. This resulted in a prompt and sustained reversal of the hypercarbia and sedation produced by the dexmedetomidine.",
keywords = "alpha adrenergic, anesthetics, intravenous, receptors, sympathetic nervous system, ventilation, α adrenoceptor agonist: dexmedetomidine",
author = "Mark Zornow",
year = "1991",
doi = "10.1016/0028-3908(91)90135-X",
language = "English (US)",
volume = "30",
pages = "1065--1071",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Ventilatory, hemodynamic and sedative effects of the α2 adrenergic agonist, dexmedetomidine

AU - Zornow, Mark

PY - 1991

Y1 - 1991

N2 - Dexmedetomedine is a potent α2 adrenergic agonist which can reduce anesthetic requirements by over 90% in rats and dogs. This study examined the effects of various doses of dexmedetomidine on the following monitored variables in New Zealand white rabbits: arterial blood gases, mean arterial pressure, respiratory rate, heart rate, and level of sedation. Following the percutaneous insertion of arterial and venous catheters, 21 rabbits received an infusion of saline or dexmedetomidine (20, 80 or 320 μg/kg). Monitored variables were recorded at 5, 15, 30 and 60 min following the infusion. Dexmedetomidine produced significant dose-dependent increases in PaCO2 and level of sedation. There were significant decreases in heart rate, PaO2 and respiratory rate. There was no significant change in mean arterial pressure even at the highest (320 μg/kg) dose. To examine the ability of an α2 adrenergic antagonist to reverse the effects of dexmedetomidine, 5 rabbits initially received 320 μg/kg of dexmedetomidine as described above. Seven minutes after completion of the infusion, 900 μg/kg of the α2 adrenergic antagonist, idazoxan, was administered. This resulted in a prompt and sustained reversal of the hypercarbia and sedation produced by the dexmedetomidine.

AB - Dexmedetomedine is a potent α2 adrenergic agonist which can reduce anesthetic requirements by over 90% in rats and dogs. This study examined the effects of various doses of dexmedetomidine on the following monitored variables in New Zealand white rabbits: arterial blood gases, mean arterial pressure, respiratory rate, heart rate, and level of sedation. Following the percutaneous insertion of arterial and venous catheters, 21 rabbits received an infusion of saline or dexmedetomidine (20, 80 or 320 μg/kg). Monitored variables were recorded at 5, 15, 30 and 60 min following the infusion. Dexmedetomidine produced significant dose-dependent increases in PaCO2 and level of sedation. There were significant decreases in heart rate, PaO2 and respiratory rate. There was no significant change in mean arterial pressure even at the highest (320 μg/kg) dose. To examine the ability of an α2 adrenergic antagonist to reverse the effects of dexmedetomidine, 5 rabbits initially received 320 μg/kg of dexmedetomidine as described above. Seven minutes after completion of the infusion, 900 μg/kg of the α2 adrenergic antagonist, idazoxan, was administered. This resulted in a prompt and sustained reversal of the hypercarbia and sedation produced by the dexmedetomidine.

KW - alpha adrenergic

KW - anesthetics

KW - intravenous

KW - receptors

KW - sympathetic nervous system

KW - ventilation

KW - α adrenoceptor agonist: dexmedetomidine

UR - http://www.scopus.com/inward/record.url?scp=0025807742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025807742&partnerID=8YFLogxK

U2 - 10.1016/0028-3908(91)90135-X

DO - 10.1016/0028-3908(91)90135-X

M3 - Article

C2 - 1684646

AN - SCOPUS:0025807742

VL - 30

SP - 1065

EP - 1071

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 10

ER -